We rank companies based on fund manager, research analyst and news sentiment
ALPN stock icon

Alpine Immune Sciences
ALPN

$64.46
0.06%
 

About: Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Employees: 142

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 17 analysts
0
News positive %
of 28 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

2,333% more call options, than puts

Call options by funds: $139K | Put options by funds: $5.72K

520% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 10

440% more first-time investments, than exits

New positions opened: 54 | Existing positions closed: 10

113% more capital invested

Capital invested by funds: $526M [Q3] → $1.12B (+$596M) [Q4]

60% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 8 (+3) [Q4]

50% more funds holding

Funds holding: 88 [Q3] → 132 (+44) [Q4]

8.24% more ownership

Funds ownership: 93.34% [Q3] → 101.58% (+8.24%) [Q4]

Research analyst outlook

17 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$18
72%
downside
Avg. target
$42
34%
downside
High target
$65
1%
upside

17 analyst ratings

14 positive
82%
neutral
18%
negative
0%
Leerink Partners
Thomas Smith
1%upside
$65
Market Perform
Downgraded
12 Apr 2024
RBC Capital
Gregory Renza
1%upside
$65
Sector Perform
Downgraded
11 Apr 2024
Morgan Stanley
Michael Ulz
1%upside
$65
Equal-Weight
Downgraded
11 Apr 2024
Guggenheim
Vamil Divan
15%downside
$55
Buy
Initiated
9 Apr 2024
HC Wainwright & Co.
Joseph Pantginis
22%downside
$50
Buy
Maintained
21 Mar 2024

Financial journalist opinion

Based on 28 articles about ALPN published over the past 30 days